Join us for a morning where biological insight meets therapeutic ambition, and the path from concept to clinic comes into sharp focus. Medicon Valley Alliance and Syngene International would like to welcome you to a Good Morning Meeting 21th of January 2026.
Engage with leaders shaping tomorrow’s treatments, and gain perspectives that strengthen scientific collaboration and innovation.
Date: Wednesday, 21 January 2026
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Welcome and introduction to Syngene Mattias Nyström, Senior Director Business Development, Northern Europe, Syngene International Ltd. |
| 9:15 | Making the Untreatable Treatable: Translating Biology into Medicine, Focus and build excellence in the translation of biological insight and concept into innovative medical treatment and thereby improve the likelihood to treat untreatable disorder Allan Wehnert, CEO & Founder, Orocidin A/S |
| 9:45 | Follow the Molecule: from Discovery to Commercialization Stephane Lefevre, Director Business development, Peptides and Oligonucleotides, Syngene International Ltd. |
| 10:00 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Allan Wehnert, CEO & Founder, Orocidin A/S
Mr. Wehnert brings more than three decades of experience in the pharmaceutical sector, with a focus on the discovery and development of new molecules for central nervous system disorders. As a trained pharmacologist, he has published 25 scientific papers in leading international journals. In his previous role as Senior Vice President for Research and Development at Initiator Pharma, he advised private equity syndicates and is the owner of Decision Insights. Allan worked at Lundbeck A/S for 25 years, during which he served as Senior Vice President and was responsible for advancing drug candidates from pre-clinical phases through to NDA and EMA approval. Allan led drug development of eight new chemical entities to FDA and EMA. In addition, Allan has performed more than 200 due diligence evaluations and has played a key role in license and acquisition deals. |
 |
Stephane Lefevre, Director Business development, Peptides and Oligonucleotides, Syngene International Ltd.
Stéphane Lefevre is Global Strategic Lead – TIDES at Syngene International, responsible for driving global growth in oligonucleotide and peptide businesses. He collaborates with cross-functional teams to deliver integrated solutions from discovery through commercialization. Stéphane holds a Ph.D. in Life Sciences from Bordeaux University and completed two postdoctoral fellowships funded by Cancer Research UK before transitioning to the pharmaceutical industry in Switzerland. At Bachem, he spent five years in commercial and leadership roles, managing key accounts and leading business development teams. Passionate about collaboration and innovation, Stéphane enjoys hiking, cycling, and skiing, and is driven by continuous learning and a commitment to excellence. |
| Organized by | In collaboration with |
 |
 |